2025-11-24 - Analysis Report
Okay, here's a report analyzing Hims & Hers Health Inc. (HIMS), broken down into sections with simple numbers and basic analysis, followed by a comprehensive summary.

**1) Return Rate Comparison (HIMS vs. S&P 500)**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc is a telehealth company offering personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 125.95%
*   **VOO (S&P 500) Cumulative Return:** 68.76%
*   **Divergence:** 57.2 (Relative Divergence: 35.2)

**Analysis:**

*   HIMS has significantly outperformed the S&P 500 (VOO) in terms of cumulative return.
*   The divergence of 57.2% indicates a substantial difference in performance, placing it above the S&P 500.
*   The relative divergence of 35.2 suggests that the current divergence is situated within the lower-middle range of its historical divergence range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta  | Cap(B) |
| :----------- | :------ | :------ | :----- | :---- | :------- |
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0   | 1.5    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0  | 1.5    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1  | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0  | 5.5    |
| 2023-2025  | 130.0% | 80.8% | 71.0%  | 0.1   | 7.9    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):** HIMS has experienced both significant declines and substantial growth over the periods analyzed. The most recent period (2023-2025) shows a very high CAGR.
*   **MDD (Maximum Drawdown):** The MDD figures are relatively high, indicating significant potential for loss during downturns.
*   **Alpha:** The Alpha values fluctuate, but are generally negative in earlier periods, suggesting underperformance relative to the market. The recent periods show positive Alpha, indicating outperformance.
*   **Beta:** Beta is close to zero, suggesting very low volatility, indicating it does not move in tandem with the market.
*   **Cap(B) (Market Capitalization in Billions):** The market cap has steadily increased, suggesting growing investor confidence.

**2) Recent Stock Price Fluctuations**

*   **Close Price:** 34.71
*   **Last Market Data:** Price: 34.71, Previous Close: 33.62, Change: 3.24%
*   **5-day SMA:** 35.2
*   **20-day SMA:** 40.83
*   **60-day SMA:** 48.85

**Analysis:**

*   The stock price closed at 34.71 with a positive change of 3.24%.
*   The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA. This indicates a downward trend over the past 60 days, although the most recent price movement suggests a potential short-term rebound.

**3) Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 18.77 (Oversold)
*   **PPO:** -1.32
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (17 shares - Very Safe - MRI:0.90). Monthly invest 1.3% of total investment ($1,000.00)
*   **Recent 20-day Relative Divergence Change:** -2.6 (short-term decline)
*   **Expected Return:** 21.4% (Over 2 years)

**Analysis:**

*   The MRI suggests a "Medium Investment" recommendation.
*   The RSI of 18.77 indicates that the stock is oversold, which could suggest a potential buying opportunity.
*   The PPO is negative, which could indicate a downward trend.
*   The negative change in relative divergence over the past 20 days confirms a recent downward trend.
*   The expected return of 21.4% suggests a potentially favorable long-term investment.

**4) Recent News & Significant Events**

*   **[2025-11-17]** Hims & Hers Announces $250 Million Share Repurchase Program.
*   **[2025-11-23]** Why Hims & Hers Stock Sank This Week.
*   **[2025-11-17]** Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today.
*   **[2025-11-04]** Hims Reverses Lower Despite Potential Deal With Novo.
*   **[2025-11-22]** $HIMS stock fell 7% this week.
*   **[2025-11-10]** Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade).

**Analysis:**

*   The news is mixed. The share repurchase program is generally positive, indicating management's confidence in the company. However, multiple news items highlight a recent decline in the stock price. A rating upgrade offsets this sentiment. The potential deal with Novo also adds a layer of complexity.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold (Mean: 2.86)
*   **Opinions:** 12
*   **Target Price (avg/high/low):** 46.00 / 85.00 / 25.00
*   **Recent Rating Changes:** No changes are indicated.

**Analysis:**

*   The analyst consensus is a "Hold," indicating a neutral outlook.
*   The average target price of $46.00 is higher than the current price, suggesting potential upside, but the wide range between high and low targets indicates uncertainty.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
| :--------- | :---- | :--------- |
| 2025-11-03 | 0.07  | 0.60 B$    |
| 2025-08-04 | 0.19  | 0.54 B$    |
| 2025-05-05 | 0.22  | 0.59 B$    |
| 2024-11-04 | 0.35  | 0.40 B$    |
| 2025-11-03 | 0.35  | 0.40 B$    |

**Analysis:**
Please note that the table has a duplicate value: 2025-11-03 | 0.35  | 0.40 B$. Assuming it to be 2024-11-04, the analysis would follow:
*   **EPS (Earnings Per Share):** EPS has fluctuated over the last few quarters, showing some volatility. Recent values are lower compared to the 2024 figures.
*   **매출 (Revenue):** Revenue has generally been increasing, with the most recent quarter showing the highest revenue.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :------------ |
| 2025-09-30 | $0.60B   | 73.80%      |
| 2025-06-30 | $0.54B   | 76.39%      |
| 2025-03-31 | $0.59B   | 73.50%      |
| 2024-12-31 | $0.48B   | 76.81%      |
| 2024-09-30 | $0.40B   | 79.16%      |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
| :----------- | :-------- | :------ |
| 2025-09-30 | $0.58B   | 2.72%   |
| 2025-06-30 | $0.56B   | 7.55%   |
| 2025-03-31 | $0.55B   | 9.01%   |
| 2024-12-31 | $0.48B   | 5.46%   |
| 2024-09-30 | $0.44B   | 17.18%  |

**Analysis:**

*   **Revenue:** Revenue shows a clear upward trend, indicating growth in the business.
*   **Profit Margin:** Profit margins have remained consistently high, suggesting efficient operations.
*   **Equity:** Equity has increased over the past year, indicating a strengthening financial position.
*   **ROE (Return on Equity):** ROE has fluctuated but shows a significant decline in the most recent quarter compared to the previous year.

**7) Comprehensive Analysis (Summary)**

Hims & Hers Health Inc. (HIMS) has outperformed the S&P 500, but the recent trend has been less positive.

**Strengths:**

*   **High Growth Potential:** The company has shown impressive revenue growth and high profit margins.
*   **Outperforming S&P 500:** HIMS has a higher cumulative return than S&P 500.
*   **Strong Brand:** Hims & Hers has carved out a niche in telehealth and personalized health solutions.
*   **Share Repurchase Program:** Indicates management's confidence.
*   **Analyst Target Price Upside:** The average analyst target price is above the current price.

**Weaknesses/Risks:**

*   **Recent Stock Price Decline:** Multiple news articles highlight a recent drop in the stock price.
*   **High Maximum Drawdown:** The stock is subject to potentially large declines.
*   **Fluctuating EPS and Declining ROE:** Recent earnings data shows some volatility in EPS and decline in ROE.
*   **Low Beta:** Can not hedge or diversify the risk of your portfolio.
*   **Analyst Consensus "Hold":** Indicates limited near-term catalysts.

**Overall:**

HIMS presents a mixed picture. While the company has demonstrated strong growth and a differentiated business model, recent stock performance and earnings data raise some concerns. The company is in an oversold position with high potential for rebound. The share repurchase program and potential deal with Novo are positive factors. Investors should weigh the growth potential against the risks and conduct thorough due diligence before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.